We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 3 februari 2017

The Lancet: [News] Venetoclax active and safe in non-Hodgkin lymphoma

[News] Venetoclax active and safe in non-Hodgkin lymphoma
New research shows that venetoclax, a selective and orally active inhibitor of BCL2, has significant activity and safety in patients with various subtypes of non-Hodgkin lymphoma.
Read more

[Comment] Sentinel-lymph-node mapping in endometrial cancer: routine practice?
The cornerstone for endometrial cancer treatment is an extrafascial removal of the uterus with bilateral salpingo oophorectomy.1 Metastatic disease in pelvic lymph nodes is the strongest prognostic factor and this information can be used to tailor adjuvant treatment.2 However, the value of a pelvic lymphadenectomy in patients with endometrial cancer is still a subject for debate.
Read more

[Articles] A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
Sentinel lymph nodes identified with indocyanine green have a high degree of diagnostic accuracy in detecting endometrial cancer metastases and can safely replace lymphadenectomy in the staging of endometrial cancer. Sentinel lymph node biopsy will not identify metastases in 3% of patients with node-positive disease, but has the potential to expose fewer patients to the morbidity of a complete lymphadenectomy.
Read more

[News] Letrozole not superior to anastrozole for early breast cancer
In a phase 3 head-to-head study (the FACE trial), 4136 postmenopausal women with hormone receptor-positive, node-positive, early-stage breast cancer were randomised to letrozole (n=2061) or anastrozole (n=2075). The results showed letrozole was not superior to anastrozole in the adjuvant setting. The final analysis was done at 709 disease-free survival events (letrozole, 341 [16·5%]; anastrozole, 368 [17·7%]). The primary endpoint of the open-label study, estimated disease-free survival at five years, was 84·9% for letrozole compared with 82·9% for anastrozole (hazard ratio [HR] 0·93, 95% CI 0·80–1·07, p=0·32).
Read more

[Articles] Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
The results of this trial do not provide any evidence for the use of bevacizumab in combination with peri-operative epiribicin, cisplatin, and capecitabine chemotherapy for patients with resectable gastric, oesophagogastric junction, or lower oesophageal adenocarcinoma. Bevacizumab might also be associated with impaired wound healing.
Read more